A recent investigation by researchers from Sinai Health in Toronto has unveiled new insights into the mechanisms by which glucagon-like peptide-1 (GLP-1) medications, such as Ozempic and Wegovy, promote liver health. Published in the journal *Cell Metabolism*, the study addresses a longstanding enigma in hepatology: how these drugs can benefit liver function even in patients who do not experience significant weight loss.
Understanding GLP-1 Drugs and Their Impact
GLP-1 receptor agonists were initially developed for diabetes management but have gained widespread attention for their effectiveness in weight reduction. Their potential, however, extends beyond weight loss, as they are now being examined as treatments for various chronic conditions, including metabolic dysfunction-associated steatohepatitis (MASH)—a severe form of fatty liver disease that can escalate to cirrhosis or liver cancer. Last December, Health Canada granted conditional approval for Wegovy as the first pharmaceutical treatment for MASH in the country.
Dr. Daniel Drucker, the lead researcher and a pioneer in GLP-1 studies, emphasised the significance of this research. “It’s a very impressive study, and a very important study,” remarked Dr. Mamatha Bhat, a liver specialist at the University Health Network. The findings offer critical evidence that may encourage both clinicians and patients to continue treatments, even in the absence of weight loss.
The Mechanism Behind Liver Improvements
The study employed advanced mouse models to challenge the prevailing assumption that weight loss is the sole driver of liver health improvements associated with GLP-1 therapies. Previous beliefs were based on the absence of GLP-1 receptors in the liver until Dr. Drucker’s groundbreaking discovery in 2021, which identified these receptors in sinusoidal endothelial cells—a rare cell type in the liver.
Dr. González-Rellán, a postdoctoral fellow in Dr. Drucker’s lab, spearheaded the research by comparing regular mice with genetically modified counterparts lacking GLP-1 receptors in their brains. Both groups were placed on a diet that induced liver disease and treated with semaglutide. Remarkably, both sets of mice exhibited liver health improvements, regardless of weight loss.
In a subsequent experiment involving mice devoid of GLP-1 receptors in their livers, the results were unexpected: these mice showed no liver benefits from semaglutide, even after significant weight loss. This highlighted the crucial role of GLP-1 receptors in liver cells for therapeutic efficacy.
Using sophisticated RNA sequencing techniques, the team discovered that activated endothelial cells effectively orchestrate liver cell activities, reducing inflammation—an essential factor in MASH progression.
Implications for Future Research and Treatment
These findings not only challenge previous assumptions in the field but also align with unpublished clinical trial data indicating that patients who experience minimal weight loss while on semaglutide still report improvements in liver function. Dr. González-Rellán believes this underscores the vast potential of GLP-1 medications, which she refers to as “metabolic medicines.”
“This field makes us stay very humble because we think we understand how they work,” she noted. “Understanding these weight loss-independent effects is quite important because many people can benefit from them.”
Why it Matters
The implications of this research extend beyond academic curiosity; they could reshape treatment paradigms for liver diseases globally. With MASH affecting approximately 25 per cent of the adult population in Canada and an estimated 1.3 billion people worldwide, the ability of GLP-1 drugs to enhance liver health, independent of weight loss, offers new hope for effective interventions. As the understanding of GLP-1 medications deepens, healthcare professionals may be better equipped to manage chronic liver conditions, ultimately leading to improved outcomes for millions.
